Chapter 45. Principles of Psychopharmacology

Noah L. Miller, M.D.; Robert L. Findling, M.D.
DOI: 10.1176/appi.books.9781585623921.467748



When clinicians contemplate the therapeutic options for psychiatric disorders, psychopharmacotherapy is often one of those options. However, there are many considerations in thinking about treatment for a youngster with a psychiatric disorder. These considerations differ from those for adults with a psychiatric disorder or for children with pediatric disorders. Factors that make psychopharmacotherapy in children and adolescents distinct from both psychopharmacotherapy in adults and pharmacotherapy for general medical conditions in children include the following:

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
TABLE 45–1. Selected areas of the psychiatric assessment that are important to pediatric psychopharmacology
Table Reference Number
TABLE 45–2. Laboratory tests to check during the psychopharmacological assessment of a pediatric patient


Achenbach TM, Rescorla LA: Manual for the ASEBA School-Age Forms and Profiles. Burlington, University of Vermont, Research Center for Children, Youth, and Families, 2001
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000
Bradley C: The behavior of children receiving Benzedrine. Am J Orthopsychiatry 94:577–585, 1937
Chen N, Aleksa K, Woodland C, et al: Ontogeny of drug elimination by the human kidney. Pediatr Nephrol 21:160–168, 2006
Conners CK: Conners 3rd Edition. North Tonawanda, NY, Multi-Health Systems, 2008
Connor D, Meltzer B: A brief history of the field, in Pediatric Psychopharmacology Fast Facts. New York, WW Norton, 2006, pp 4–6
Hazell P, O'Connell D, Heathcote D, et al: Tricyclic drugs for depression in children and adolescents. Cochrane Database of Systematic Reviews 2002, Issue 2. Art. No.: CD002317. DOI: 10.1002/14651858.CD002317
Ivanova MY, Dobrean A, Dopfner M, et al: Testing the 8-syndrome structure of the Child Behavior Checklist in 30 societies. J Clin Child Adolesc Psychol 36:405–417, 2007
Jatlow PI: Psychotropic drug disposition during development, in Psychiatric Pharmacosciences of Children and Adolescents. Edited by Popper C. Washington, DC, American Psychiatric Press, 1987, pp 27–44
Kearns GL, Abdel-Rahman SM, Alander SW, et al: Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167, 2003
McNally P, McNichols F, Oslizlok P: The QT interval and psychotropic medications in children: recommendations for clinicians. Eur Child Adolesc Psychiatry 16:33–47, 2007
Murrin LC, Sanders JD, Bylund DB: Comparison of the maturation of the adrenergic and serotonergic neurotransmitter systems in the brain: implications for differential drug effects on juveniles and adults. Biochem Pharmacol 73:1225–1236, 2007
U.S. Food and Drug Administration: Public Health Advisory: Suicidality in Children and Adolescents Being Treated with Anti-depressant Medications. October 15, 2004. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm155488.htm. Accessed June 23, 2009.
U.S. Food and Drug Administration: Safety Alerts for Human Medical Products: Antiepileptic Drugs. January 31, 2008. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm074939.htm. Accessed June 23, 2009.
Vitiello B: Developmental aspects of pediatric psychopharmacology, in Clinical Manual of Child and Adolescent Psychopharmacology. Edited by Findling RL. Washington, DC, American Psychiatric Publishing, 2008, pp 1–31
Zametkin AJ, Ernst M, Silver R: Laboratory and diagnostic testing in child and adolescent psychiatry: a review of the past 10 years. J Am Acad Child Adolesc Psychiatry 37:464–472, 1998

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
Which of the following goals needs to be reached during a psychiatric assessment of youth before considering psychopharmacological treatment?
Which of the following medications is least likely to affect electrocardiogram (ECG) at therapeutic doses?
All of the following statements regarding the principles of diagnosing and treating youth with psychiatric disorders are correct except
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 36.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 1.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 2.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 3.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 4.  >
Topic Collections
Psychiatric News
PubMed Articles
Pediatric psychopharmacology in primary care: a conceptual framework. Adolesc Med State Art Rev 2013;24(2):371-90, vii.
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation